Yousif Capital Management LLC Trims Stock Holdings in HCA Healthcare, Inc. $HCA

Key Points

• Yousif Capital Management LLC reduced its holdings in HCA Healthcare by 4.1%, bringing its total shares to 18,554 worth approximately $7,108,000.
• HCA Healthcare reported an earnings per share (EPS) of $6.84 for the last quarter, exceeding analyst expectations by $0.64, with total revenue reaching $18.61 billion.
• The company has set its fiscal year 2025 EPS guidance at 25.500-27.000, while analysts predict an EPS of 24.98 for the current fiscal year.

Yousif Capital Management LLC decreased its holdings in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 4.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,554 shares of the company's stock after selling 790 shares during the period. Yousif Capital Management LLC's holdings in HCA Healthcare were worth $7,108,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC purchased a new position in shares of HCA Healthcare during the fourth quarter worth approximately $1,021,000. Farther Finance Advisors LLC increased its holdings in HCA Healthcare by 26.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,141 shares of the company's stock worth $395,000 after purchasing an additional 242 shares during the period. GAMMA Investing LLC increased its stake in shares of HCA Healthcare by 17.6% during the first quarter. GAMMA Investing LLC now owns 4,931 shares of the company's stock valued at $1,704,000 after buying an additional 737 shares during the period. Sowell Financial Services LLC purchased a new position in shares of HCA Healthcare during the first quarter valued at $999,000. Finally, Grove Bank & Trust increased its position in HCA Healthcare by 14.9% during the 1st quarter. Grove Bank & Trust now owns 833 shares of the company's stock valued at $288,000 after purchasing an additional 108 shares during the period. Hedge funds and other institutional investors own 62.73% of the company's stock.

HCA Healthcare Stock Performance

HCA Healthcare stock opened at $418.34 on Wednesday. The business's 50-day simple moving average is $407.16 and its two-hundred day simple moving average is $376.85. The company has a market cap of $97.89 billion, a PE ratio of 17.58, a PEG ratio of 1.29 and a beta of 1.40. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $439.01.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, beating analysts' consensus estimates of $6.20 by $0.64. The firm had revenue of $18.61 billion for the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.HCA Healthcare's revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.50 earnings per share. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were paid a $0.72 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare's dividend payout ratio is presently 12.11%.

Insider Activity at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the sale, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of HCA Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $444.00 price target on shares of HCA Healthcare in a report on Tuesday, October 7th. Truist Financial set a $460.00 target price on HCA Healthcare in a research note on Tuesday. Barclays lifted their price objective on shares of HCA Healthcare from $390.00 to $445.00 and gave the stock an "overweight" rating in a research report on Thursday, September 18th. Finally, Wells Fargo & Company lifted their price objective on shares of HCA Healthcare from $375.00 to $412.00 and gave the stock an "equal weight" rating in a research report on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $431.07.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.